Cipla traded at 1,038.35 this Wednesday August 10th, increasing 8.80 or 0.85 percent since the previous trading session. Looking back, over the last four weeks, Cipla gained 9.58 percent. Over the last 12 months, its price rose by 14.12 percent. Looking ahead, we forecast Cipla to be priced at 1,003.90 by the end of this quarter and at 918.51 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Cipla 1,038.35 8.80 0.85% 14.12%
Dr.Reddys Laboratories 4,243.30 19.95 0.47% -10.57%
Sun Pharmaceuticals 919.70 9.30 1.02% 17.98%
UPL 765.30 16.15 2.16% -1.10%

Indexes Price Day Year
SENSEX 58817 -35.78 -0.06% 7.87%
NIFTY 50 17535 9.65 0.06% 7.69%

Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled accessory devices. Cipla Global Access is a tender-based institutional business that concentrates on approximately four therapy areas: human immunodeficiency virus/acquired immuno deficiency syndrome (HIV/AIDS), malaria, multi drug-resistant tuberculosis and reproductive health. The Company offers its products for the therapeutic areas, including cardiovascular, children's health, dermatology and cosmetology, diabetes, HIV/AIDS, infectious diseases and critical care, malaria, neurosciences, oncology, ophthalmology, osteoporosis, respiratory, urology and women's health.